Evaluation Taking a Closer Look at S1P Receptor Modulators in Ulcerative Colitis: Practical Considerations and Optimal Positioning Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the mechanism of action and clinical role for S1PR modulators in the management of UC 5 4 3 2 1 Evaluate the most recent safety and efficacy data associated with current and emerging S1PR modulators 5 4 3 2 1 Outline patient-centered and practical considerations to tailor care and address adverse events 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Stephen B. Hanauer, MD, MACG 5 4 3 2 1 Christina Y. Ha, MD, FACG, AGAF 5 4 3 2 1 Adam Cheifetz, MD 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients do you encounter with UC on a weekly basis? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Sphingosine-1 receptor (S1PR) modulators mitigate ulcerative colitis (UC) pathogenesis through which mechanism? Accumulation of inflammatory cytokines in the GI system Dysregulated Th1 immune response Pathological changes in the gut microbiome Reducing circulating lymphocyte counts Data from the TRUE NORTH study demonstrated that 37% of patients treated with ______ maintained clinical remission. Amiselimod Etrasimod Fingolimod Ozanimod Based on current data, S1PR modulators are potentially best positioned for: First-line induction therapy for biologic naïve patients Maintenance therapy for biologic-experienced patients Induction and maintenance for UC mesalamine failures Induction therapy with an eventual switch to biologic agent for maintenance How confident are you now in your ability to appropriately utilize S1PR modulators and manage/mitigate AEs in clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident How confident are you now in your ability to manage/mitigate potential AEs associated with S1PR modulators in clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Engage in communication regarding UC treatment options and goals with my patients Evaluate emerging clinical data on the safety and efficacy of current and emerging S1PR modulators for UC treatment Utilize S1PR modulators in clinical practice for UC where appropriate Incorporate AE mitigation and management strategies for S1PR modulator therapy where appropriate Use guideline recommendations to identify patients who qualify for S1PR modulator induction or maintenance treatment Employ appropriate strategies to prevent or manage potential AEs as a result of S1PR modulator treatment Other (please specify): Previous